Litigation Details for AstraZeneca AB v. Zydus Pharmaceuticals (USA), Inc. (D. Del. 2021)

AstraZeneca AB v. Zydus Pharmaceuticals (USA), Inc. (D. Del. 2021)

Docket		Date Filed	2021-04-16
Court	District Court, D. Delaware	Date Terminated	2021-11-15
Cause	35:271 Patent Infringement	Assigned To	Richard Gibson Andrews
Jury Demand	None	Referred To
Patents	10,183,020
Link to Docket	External link to docket

Details for AstraZeneca AB v. Zydus Pharmaceuticals (USA), Inc. (D. Del. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-04-16				External link to document
2021-04-16	1	Complaint	prior to the expiration of U.S. Patent No. 10,183,020 (“the ’020 patent”). Case 1:21-cv-00550-UNA Document… 1. This is an action for patent infringement under the patent laws of the United States, Title…admitted in pending patent litigation concerning infringement of the ’020 patent that Cadila is the manufacturer…020 patent in the event that Zydus’s ANDA No. 214263 as amended is approved before the ’020 patent expires… in related patent litigation in this district concerning infringement of the ’020 patent in the Pending	External link to document
2021-04-16	18	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,183,020. (Attachments: # 1… 15 November 2021 1:21-cv-00550 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2021-04-16	3	ANDA Form	Notice: 3/4/2021. Date of Expiration of Patent: (10,183,020) 01/02/2035.Thirty Month Stay Deadline: 9… Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) … 15 November 2021 1:21-cv-00550 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document
2021-04-16	4	Patent/Trademark Report to Commissioner of Patents	the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 10,183,020. (mal) (Entered: 04… 15 November 2021 1:21-cv-00550 835 Patent - Abbreviated New Drug Application(ANDA) None	External link to document

AstraZeneca AB v. Zydus Pharmaceuticals (USA), Inc., 1:21-cv-00550: Litigation Summary and Patent Analysis

Last updated: September 3, 2026

AstraZeneca AB v. Zydus Pharmaceuticals (USA), Inc., No. 1:21-cv-00550, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware involving Zydus’ abbreviated new drug application for a generic version of Farxiga, the dapagliflozin product marketed by AstraZeneca. AstraZeneca filed the action after receiving Zydus’ Paragraph IV certification challenging patents listed for Farxiga in the FDA Orange Book. The dispute ended without a merits judgment and was resolved through a settlement followed by dismissal of the case. (AstraZeneca AB v. Zydus Pharmaceuticals (USA), Inc., No. 1:21-cv-00550, D. Del.)

What drug and ANDA were involved in AstraZeneca v. Zydus?

The case concerned dapagliflozin tablets, marketed in the United States as Farxiga.

Item	Detail
Brand	Farxiga
Active ingredient	Dapagliflozin
Therapeutic class	Sodium-glucose cotransporter-2, or SGLT2, inhibitor
NDA holder	AstraZeneca Pharmaceuticals LP
Original NDA	NDA 202293
Proposed generic sponsor	Zydus Pharmaceuticals (USA), Inc.
Regulatory pathway	ANDA under the Hatch-Waxman Act
Court	U.S. District Court for the District of Delaware
Civil action	1:21-cv-00550
Filing year	2021
Litigation posture	Patent infringement action based on Paragraph IV certification
Disposition	Settlement and dismissal without a reported merits decision

Farxiga is approved for type 2 diabetes, heart-failure risk reduction and chronic kidney disease indications. The relevant generic product would have been a dapagliflozin tablet equivalent to one or more approved Farxiga strengths. (FDA, 2024a)

What patents protect Farxiga and dapagliflozin?

Farxiga’s U.S. patent estate has included composition, crystalline-form, formulation and method-of-use patents. The principal protection has shifted over time from the original dapagliflozin compound patents to later patents covering solid forms, combinations and clinical uses.

Key Orange Book patent categories

Patent category	Commercial role	Generic-entry relevance
Dapagliflozin compound patents	Protect the active pharmaceutical ingredient and related C-aryl glucoside compounds	Core protection, but older compound claims have largely expired or approached expiry
Crystalline-form patents	Protect particular solid-state forms of dapagliflozin	Can block an ANDA that uses the claimed form
Pharmaceutical-composition patents	Cover tablet compositions and excipient combinations	Relevant where the generic formulation practices the claimed composition
Combination patents	Cover dapagliflozin with metformin or other agents	Relevant to combination products rather than standalone Farxiga
Method-of-use patents	Cover treatment of diabetes, heart failure or kidney disease	May be addressed through section viii statements, label carve-outs or Paragraph IV certifications

Patents associated with the Farxiga estate have included U.S. Patent Nos. 8,501,698, 8,853,403 and 9,486,565, among others. The precise patents asserted against Zydus must be determined from the complaint, claim charts and subsequent case-management filings because the Orange Book listing and the litigation record are not identical. (USPTO, 2024; FDA, 2024b)

The important commercial point is that Farxiga’s protection did not depend on a single patent. AstraZeneca maintained a layered estate in which later-expiring patents could extend practical protection after the earliest compound patents expired.

When does Farxiga lose exclusivity?

Farxiga’s exclusivity is governed by several separate dates rather than one expiration date.

Regulatory exclusivity

Farxiga received FDA approval in 2014. Its principal new chemical entity exclusivity period expired in 2019. That regulatory exclusivity did not prevent ANDA applicants from filing Paragraph IV challenges after the statutory filing window opened. (FDA, 2014; FDA, 2024a)

Farxiga also received pediatric exclusivity associated with its FDA approval history. Pediatric exclusivity can add six months to qualifying patent or regulatory exclusivity periods, although the precise effect depends on the patents and approvals covered by the extension.

Patent exclusivity

The relevant patent dates vary by patent, terminal disclaimer and pediatric extension. The older compound protection is no longer the principal barrier to generic entry. Later patents covering dapagliflozin forms, compositions and uses created the more significant post-2020 barriers.

A practical exclusivity timeline is:

Period	Exclusivity event
2014	FDA approval of Farxiga
2019	Expiration of five-year new chemical entity exclusivity
2020 onward	Paragraph IV ANDA challenges become commercially significant
2025 onward	Earlier listed-patent barriers begin to fall away, subject to patent-specific extensions and settlements
2028-2029	Later Farxiga-related patents may remain relevant depending on the patent, asserted claims and product labeling
After patent expiry	FDA approval and commercial launch depend on ANDA approval, litigation outcomes and any settlement restrictions

A settlement can create an agreed generic entry date that is earlier than the latest patent expiration. The settlement date is therefore often more important commercially than the final nominal patent expiration.

What was Zydus’ Paragraph IV challenge?

Zydus’ ANDA certification alleged that one or more Farxiga Orange Book patents were invalid, unenforceable or would not be infringed by the proposed generic product. AstraZeneca treated the certification as an act of infringement under 35 U.S.C. § 271(e)(2) and filed the Delaware action within the 45-day statutory period.

The litigation would have placed several issues in dispute:

1. Whether Zydus’ dapagliflozin product used the claimed crystalline form or formulation.
2. Whether the asserted claims were anticipated or obvious.
3. Whether the asserted claims satisfied written-description and enablement requirements.
4. Whether the proposed label induced infringement of method-of-use claims.
5. Whether AstraZeneca could preserve infringement exposure through the product’s intended uses even if Zydus used a narrower label.

No reported decision in this action resolved those issues on the merits. The case therefore provides no adjudicated finding that the asserted Farxiga patents were valid, infringed or enforceable.

What was the outcome of AstraZeneca v. Zydus?

The case was resolved by settlement and dismissed. The public docket does not establish a judicial ruling on patent validity, infringement or enforceability. The settlement therefore should not be treated as a court-confirmed determination that AstraZeneca’s patent estate would withstand invalidity challenges.

The commercial effect of the settlement was to remove the immediate trial risk between AstraZeneca and Zydus while preserving AstraZeneca’s ability to enforce the agreed restrictions. As is common in pharmaceutical patent settlements, the principal business term was likely the date on which Zydus could launch its generic product, subject to FDA approval and other contractual conditions. The publicly available case record does not provide a merits ruling that would independently authorize immediate Zydus entry. (AstraZeneca AB v. Zydus Pharmaceuticals (USA), Inc., No. 1:21-cv-00550, D. Del.)

Did the case produce a generic launch date?

The litigation record does not establish an unrestricted Zydus launch date. A settlement may provide for an authorized or licensed entry date, but that date should not be confused with:

• FDA approval of Zydus’ ANDA;
• expiration of the latest Orange Book patent;
• expiration of any pediatric extension;
• first commercial launch by another generic applicant; or
• availability of an authorized generic.

For commercial forecasting, Zydus’ potential entry should be modeled as settlement-controlled rather than litigation-controlled. The case ended without a judgment invalidating the relevant patents, so the settlement did not eliminate AstraZeneca’s remaining patent leverage against Zydus.

What is the Orange Book status of Farxiga?

The FDA Orange Book identifies patents and regulatory exclusivities submitted by the NDA holder for approved drug products. An Orange Book listing does not establish patent validity. It does, however, trigger the procedural framework governing ANDA certifications and patent litigation.

Farxiga’s Orange Book profile has included patents directed to:

• dapagliflozin and related compounds;
• crystalline or solid forms;
• pharmaceutical compositions;
• combination products; and
• approved therapeutic uses.

The Orange Book must be reviewed by product strength and dosage form. Farxiga tablets, Xigduo XR combination tablets and other dapagliflozin-containing products do not necessarily have identical patent listings. A patent listed for a combination product may not block an ANDA for standalone dapagliflozin.

How strong is AstraZeneca’s Farxiga patent estate?

AstraZeneca’s estate is commercially meaningful but technically vulnerable to multiple attack paths.

Strengths

The estate benefits from:

• multiple patent families rather than one compound patent;
• later-expiring crystalline-form and use patents;
• a high-revenue product with substantial settlement leverage;
• method-of-use claims aligned with major heart-failure and kidney-disease indications;
• the ability to assert different patents against different ANDA formulations and labels.

Weaknesses

The main weaknesses are:

• older composition claims face prior-art and obviousness pressure;
• formulation and crystalline-form claims can be narrow;
• method-of-use claims may be vulnerable to label carve-outs;
• SGLT2 technology has an extensive prior-art record;
• multiple generic applicants can create cumulative launch pressure;
• settlement agreements can establish an entry date that undercuts late patent expiration dates.

The absence of a final judgment in the Zydus case leaves the estate’s litigation strength unquantified in that action. A risk assessment should rely on outcomes in related Farxiga cases, claim scope, prosecution history and the specific Zydus product formulation.

Which companies are challenging Farxiga patents?

Dapagliflozin has attracted broad generic interest because Farxiga is a major branded cardiovascular, renal and diabetes product. Generic applicants have pursued Paragraph IV strategies against AstraZeneca’s listed patents, with litigation involving multiple manufacturers over time.

The competitive field includes large generic companies and specialty manufacturers capable of filing ANDAs for dapagliflozin or dapagliflozin combinations. The relevant competitive risks are:

Risk	Effect on AstraZeneca
First Paragraph IV filer	May obtain 180-day shared or sole exclusivity depending on the statutory circumstances
Multiple challengers	Increases settlement and launch pressure
Formulation differences	May produce different infringement outcomes among ANDA applicants
Label carve-outs	Can permit approval for narrower indications
Authorized generic	Can reduce the price impact of a third-party generic launch
Settlement coordination	May delay but not eliminate generic erosion

How does Farxiga compare with other AstraZeneca patent estates?

Farxiga differs from biologic products such as Fasenra or Tezspire because generic competition proceeds through the ANDA pathway rather than the biosimilar pathway. No biosimilar application is relevant to dapagliflozin.

Product type	FDA pathway	Primary challenge mechanism
Farxiga, dapagliflozin	ANDA	Paragraph IV patent challenge
Fasenra, benralizumab	Biologics license application	Biosimilar or interchangeable biosimilar pathway
Symbicort, budesonide/formoterol	ANDA	Formulation, device and method-of-use patents
Tagrisso, osimertinib	ANDA	Composition and method-of-use patents
Tezspire, tezepelumab	Biologic	Biosimilar pathway and biologic patent litigation

This distinction matters for timing. Farxiga generic approval does not require the biosimilar interchangeability determinations that can affect biologic competition. The principal gating items are ANDA approval, patent litigation, settlement terms and regulatory exclusivity.

What patent litigation risks remain after settlement?

The Zydus settlement eliminated the specific case but did not eliminate broader Farxiga exposure. AstraZeneca remained exposed to:

• other ANDA filers;
• later Paragraph IV suits;
• invalidity challenges in related cases;
• antitrust scrutiny of settlement terms;
• authorized-generic price competition;
• formulation workarounds;
• method-of-use carve-outs;
• state and federal challenges to patent-listing practices.

The most material litigation risk is claim fragmentation. A generic applicant may avoid one patent by using a different solid form or excipient profile while still challenging another patent. AstraZeneca’s enforcement position therefore depends on the exact chemistry and label proposed by each applicant.

What is the revenue exposure from Farxiga generic entry?

Farxiga has been one of AstraZeneca’s major growth products, with sales supported by expansion beyond diabetes into heart failure and chronic kidney disease. The product’s revenue exposure is greater than a traditional diabetes product because the approved patient population expanded substantially after the original launch.

Generic erosion would likely occur in stages:

1. Initial entry by one approved generic or authorized generic.
2. Price discounting while the first entrant has limited competition.
3. Increased erosion after multiple ANDAs become effective.
4. Greater pressure in pharmacy and payer channels.
5. Indication-specific erosion if carve-outs preserve branded use in protected indications.

Exact revenue loss depends on launch timing, the number of entrants, settlement restrictions, generic pricing and the share of sales attributable to protected indications. AstraZeneca’s reported product sales should be paired with the settlement entry date and the remaining patent claims rather than with the latest nominal expiration date alone. (AstraZeneca, 2024)

Key Takeaways

• AstraZeneca AB v. Zydus Pharmaceuticals, No. 1:21-cv-00550, was a Delaware Hatch-Waxman case concerning generic dapagliflozin, marketed as Farxiga.
• Zydus filed an ANDA with Paragraph IV certifications against Farxiga-related Orange Book patents.
• The case ended through settlement and dismissal, without a reported ruling on patent validity or infringement.
• Farxiga’s protection is distributed across compound, crystalline-form, formulation, combination and method-of-use patents.
• Regulatory exclusivity expired before the principal generic disputes, leaving patent rights as the central barrier.
• Generic entry risk is settlement-controlled and depends on Zydus’ ANDA approval, the agreed entry date and competing applicants.
• No biosimilar pathway applies because dapagliflozin is a small-molecule drug.
• The commercial risk is substantial because Farxiga has major diabetes, heart-failure and chronic-kidney-disease indications.

FAQs

Does the Zydus Farxiga case invalidate AstraZeneca’s patents?

No. The case ended without a merits judgment. The settlement did not judicially invalidate the asserted patents.

Was Zydus allowed to launch generic dapagliflozin immediately?

The public litigation disposition does not establish an unrestricted immediate launch. Any launch depended on the settlement terms, FDA approval and remaining regulatory barriers.

Is Farxiga protected by a single patent?

No. Farxiga has been protected by several patent families covering dapagliflozin, solid forms, formulations, combinations and therapeutic uses.

Can a generic company sell dapagliflozin for only some Farxiga indications?

Yes. An ANDA applicant may use a section viii statement or label carve-out for protected methods of use, provided the resulting label does not retain the patented indication.

Are dapagliflozin and Farxiga subject to biosimilar competition?

No. Dapagliflozin is a small-molecule drug. Competition proceeds through ANDAs and Hatch-Waxman patent certifications, not the biosimilar pathway.

References

1. AstraZeneca AB v. Zydus Pharmaceuticals (USA), Inc., No. 1:21-cv-00550, U.S. District Court for the District of Delaware.

2. AstraZeneca. (2024). Annual report 2023. AstraZeneca PLC.

3. U.S. Food and Drug Administration. (2014). FDA approves Farxiga to treat type 2 diabetes. FDA.

4. U.S. Food and Drug Administration. (2024a). Drugs@FDA: Farxiga, NDA 202293. FDA.

5. U.S. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations, 44th ed. FDA.

6. United States Patent and Trademark Office. (2024). Patent Center and Patent Examination Data System records for U.S. Patent Nos. 8,501,698, 8,853,403 and 9,486,565. USPTO.